Navigation Links
Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
Date:12/21/2010

DEERFIELD, Ill. and OSAKA, Japan, Dec. 21, 2010 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed settlements with all defendants in patent litigation brought against the companies in response to their Abbreviated New Drug Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl), ACTOplus met® (pioglitazone HCl and metformin HCl), and duetact® (pioglitazone HCl and glimepiride). Takeda filed the lawsuits to enforce several patents that expire in 2016 relating to ACTOS, ACTOplus met, and duetact.

Agreements have been reached with the following generic companies and their respective affiliates: Mylan, Inc. ("Mylan"), Alphapharm Pty. Ltd. ("Alphapharm"), Watson Pharmaceuticals, Inc. ("Watson"), Ranbaxy Laboratories Limited ("Ranbaxy"), Sandoz, Inc. ("Sandoz"), Teva Pharmaceutical Industries, Ltd. ("Teva"), Torrent Pharmaceuticals Limited ("Torrent"), Dr. Reddy's Laboratories, Limited ("Dr. Reddy"), Wockhardt Limited ("Wockhardt"), Synthon Pharmaceuticals, Inc. ("Synthon") and Breckenridge Pharmaceutical, Inc. ("Breckenridge") (collectively, "the Synthon defendants"), and Aurobindo Pharma Limited ("Aurobindo").

Based on these settlements, Takeda continues to operate in accordance with its Mid-Range Plan, announced in May 2010, which assumes that market entry of generic ACTOS will occur on August 17, 2012, and that market entry of generic ACTOplus met and generic duetact will occur on December 14, 2012. With these settlements, the forecasts of Takeda's consolidated results for the full year of fiscal 2010 announced on October 29, 2010 will not be changed.

Takeda is the inventor and developer of ACTOS, which was launched commercially in the United States (U.S.) in 1999 for the treatment of type 2 diabetes and has been prescribed for more than 10
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 28, 2014 China Nepstar Chain ... the "Company"), a leading retail drugstore chain in ... stores, today announced its unaudited financial results for ... Financial HighlightsFor the quarter ended June 30, 2014: ... million) compared to RMB638.8 million in the second ...
(Date:8/27/2014)... , Aug. 27, 2014 TWi Pharmaceuticals, ... approval from the United States Food and Drug ... (ANDA) for megestrol acetate 125mg/ml oral suspension, the ... is the first-to-file and under Hatch Waxman rules, ... marketing exclusivity.  TWi has completed the pre-launch preparation ...
(Date:8/27/2014)... 27, 2014 Reportbuyer.com has added ... Collaborative R&D Terms & Agreements in Pharma, ... The Collaborative R&D Terms and ... provides comprehensive understanding and unprecedented access to ... into by the worlds leading life science ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 11TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 4Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 6Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 7Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 8Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 9
... Mylan Inc. (Nasdaq: MYL ) today ... final approval from the U.S. Food and Drug Administration ... Ibandronate Sodium Tablets, 150mg. This product is the generic ... treatment and prevention of osteoporosis in postmenopausal women. ...
... YORK, March 20, 2012 Reportlinker.com ... report is available in its catalogue: ... Market: Western Europe Market Size, Segment ... http://www.reportlinker.com/p0797078/Nutraceuticals-Product-Market-Western-Europe-Market-Size-Segment-And-Country-Analysis-And-Forecasts-2007-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Nutraceutical ...
Cached Medicine Technology:Nutraceuticals Product Market: Western Europe Market Size, Segment And Country Analysis And Forecasts (2007-2017) 2Nutraceuticals Product Market: Western Europe Market Size, Segment And Country Analysis And Forecasts (2007-2017) 3Nutraceuticals Product Market: Western Europe Market Size, Segment And Country Analysis And Forecasts (2007-2017) 4
(Date:8/28/2014)... 2014 Alpine, NJ resident Othon Mourkakos ... team, Zebras In Tiaras, to benefit the Immune Deficiency ... October 26, 2014 in Foley Square, New York. ... Primary immunodeficiency diseases (PI) are a group of more ... of the body’s immune system is missing or functions ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 MarijuanaDoctors.com ... California physician, James Patel M.D. of Livermore, California. As ... best and most qualified physicians, and in accordance with ... our patients to Dr. Patel’s practice. , Initially finding ... a young age, Dr. Patel was shaped by his ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 MMAR Medical ... program is a chance for regular customers to enjoy ... without the need for a wholesale license. It’s a ... semi-professional athletic programs and others who regularly purchase medical ... , “Whether supporting your own active lifestyle or those ...
(Date:8/28/2014)... 28, 2014 The Pulmonica is a ... resonant, meditative sounds that can be felt vibrating in ... to use it – just taking long, slow, deep ... , Here are some examples of how to ... your eyes, relax, and maintain good posture. Try to ...
(Date:8/28/2014)... 28, 2014 Coveros, Inc., the ... that it has partnered with InfoZen on the ... start date of 2/4/2014 with U.S. Citizenship and ... (DHS) agency that oversees lawful immigration to the ... InfoZen will automate the integration and delivery of ...
Breaking Medicine News(10 mins):Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 2Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 3Health News:Army Colonel Dr. James Patel Joins the Medical Marijuana Industry 4Health News:MMAR Medical Announces Customer Membership Program 2Health News:Ever Thought of Meditating With a Harmonica; Harmonica Techs, Inventors of the Pulmonica® Pulmonary Harmonica®, Present Tips on How to Relax with Soothing Sounds 2Health News:Coveros Partners with InfoZen on USCIS Transformation Integration Award 2
... 1, 2011) Two new studies published in the ... (JNM) provide insight into the potential of positron ... and to identify pharmaceuticals to slow the progress of ... the Alzheimer,s Association guidelines for detecting Alzheimer,s-related brain changes ...
... , MONDAY, Aug. 1 (HealthDay News) -- Despite the ... -- which can be done at home or in day ... However, colon cleansing can cause serious side effects ranging ... the report say. Colon cleansing -- also called colonic ...
... breast cancer patients who don,t respond to tamoxifen ... from the Kimmel Cancer Center at Jefferson ... combined with dasatinib, a protein-tyrosine kinase inhibitor, reverses ... surrounding tissue by normalizing glucose intake and reducing ...
... , SUNDAY, July 31 (HealthDay News) -- A ... been pinpointed by a team of researchers working together ... The PYHIN1 gene variant was not present in ... gene variant to be identified in black Americans. ...
... obesity are heavily rooted in the notion of personal ... healthy foods and portion sizes consistent with weight loss ... According to preventive medicine and behavioral experts at Rush ... that views obesity as a result of neurobehavioral processes ...
... By Amanda Gardner HealthDay Reporter , FRIDAY, ... Drug Administration should scrap the system it uses to ... joints and heart pacemakers, according to a highly anticipated ... come up with a legally sound process that ensures ...
Cached Medicine News:Health News:New JNM research supports upcoming Alzheimer's disease guidelines 2Health News:Colon Cleansing Has No Health Benefit, May Harm: Report 2Health News:Leukemia drug reverses tamoxifen-resistance in breast cancer cells 2Health News:Obesity counseling should focus on neurobehavioral processes, not personal choice, researchers say 2Health News:Obesity counseling should focus on neurobehavioral processes, not personal choice, researchers say 3Health News:Report Urges New Review System for Medical Devices 2Health News:Report Urges New Review System for Medical Devices 3
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled double bevel. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
18 gauge straight. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Medicine Products: